Cubicin and Opdivo drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Cubicin (daptomycin) and Opdivo (nivolumab). Common drug interactions include encephalitis among females.
The phase IV clinical study analyzes what interactions people have when they take Cubicin and Opdivo. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.
What is Cubicin?
Cubicin has active ingredients of daptomycin. It is often used in infection. eHealthMe is studying from 7,991 Cubicin users. Check the latest studies of Cubicin.
What is Opdivo?
Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.
13 people who take Cubicin and Opdivo together, and have interactions are studied.

What are the common drug interactions of Cubicin and Opdivo, by gender? *:
female:
- Encephalitis (inflammation of the brain)
- Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
- Rash
- Secondary adrenocortical insufficiency (inadequate secretion of acth by the pituitary gland)
- Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults)
- Malignant neoplasm progression (cancer tumour came back)
- Pemphigoid (tense blisters on the skin)
- Pleural effusion (water on the lungs)
- Sepsis (a severe blood infection that can lead to organ failure and death)
- Heparin-induced thrombocytopenia
male:
n/a
What are the common drug interactions of Cubicin and Opdivo, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults)
- Malignant neoplasm progression (cancer tumour came back)
- Pemphigoid (tense blisters on the skin)
- Pleural effusion (water on the lungs)
- Sepsis (a severe blood infection that can lead to organ failure and death)
- Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
60+:
- Encephalitis (inflammation of the brain)
- Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
- Rash
- Secondary adrenocortical insufficiency (inadequate secretion of acth by the pituitary gland)
- Heparin-induced thrombocytopenia
- Skin disorder (skin disease)
- Type 1 diabetes mellitus
- Nephritis (inflammation of the nephrons in the kidneys)
- Pancreatitis (inflammation of pancreas)
- Staphylococcal infection (an infection with staphylococcus bacteria)
What are the existing conditions these people have? *
- Staphylococcal Infection (an infection with staphylococcus bacteria): 6 people, 46.15%
- Gastric Cancer (stomach cancer): 6 people, 46.15%
- Thyrotoxic Crisis (a life threatening condition due to excess secretion of thyroid hormone): 4 people, 30.77%
- Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 30.77%
- Metastases To Lung (cancer spreads to lung): 4 people, 30.77%
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 30.77%
- Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 15.38%
- Pleural Effusion (water on the lungs): 2 people, 15.38%
- Pemphigoid (tense blisters on the skin): 2 people, 15.38%
- Malignant Melanoma (skin cancer rises from melancytes): 2 people, 15.38%
* Approximation only. Some reports may have incomplete information.
Do you take Cubicin and Opdivo?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Cubicin and Opdivo:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Cubicin:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Opdivo:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Cubicin and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Opdivo and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .
- Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .
How the study uses the data?
The study uses data from the FDA. It is based on daptomycin and nivolumab (the active ingredients of Cubicin and Opdivo, respectively), and Cubicin and Opdivo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Cetirizine Hydrochloride And Pseudoephedrine Hydrochloride and Diphenhydramine Hydrochloride drug interactions for women aged 40-49 - 4 seconds ago
- Could Aldactone cause Accident? - 7 seconds ago
- Nuclear Magnetic Resonance Imaging Brain and drugs of ingredients of methotrexate sodium - 10 seconds ago
- Drug Abuse And Dependence and drugs of ingredients of disulfiram - 15 seconds ago
- Could Xeloda cause Abdominal Rigidity? - 19 seconds ago
- Lyrica and Open Angle Glaucoma for Women aged 50-59 - 25 seconds ago
- Lyrica and Congenital Glaucoma for Women aged 50-59 - 25 seconds ago
- Lyrica and Closed Angle Glaucoma for Women aged 50-59 - 25 seconds ago
- Lyrica and Chronic Glaucoma for Women aged 50-59 - 26 seconds ago
- Lyrica and Glaucoma for Women aged 50-59 - 26 seconds ago